Pelthos Therapeutics (PTHS) Free Cash Flow (2023 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Free Cash Flow of -$6.3 million for Q4 2025, down 833.13% year-over-year from $852776.9 in Q4 2024, and up 59.03% quarter-over-quarter from -$15.3 million in Q3 2025.
Pelthos Therapeutics (PTHS) Free Cash Flow (2023 - 2026) Analysis & Trends
Pelthos Therapeutics' Free Cash Flow history runs 3 years deep, the most recent figure standing at -$6.3 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 833.13% year-over-year to -$6.3 million; the TTM figure through Dec 2025 stood at -$22.6 million (down 290.02% YoY), while the FY2025 annual figure was -$22.7 million, down 291.73% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$6.3 million, up from -$15.3 million in the prior quarter.
- The five-year high for Free Cash Flow was -$173369.0 in Q1 2023, with the low at -$15.3 million in Q3 2025.
- The 3-year median for Free Cash Flow is -$539635.5 (2025), against an average of -$2.4 million.
- Peak annual rise in Free Cash Flow reached 84.85% in 2025, while the deepest fall reached 8487.18% in 2025.
- Pelthos Therapeutics' Free Cash Flow stood at -$356807.0 in 2023, then slumped by 87.78% to -$670000.0 in 2024, then tumbled by 833.13% to -$6.3 million in 2025.
- Business Quant data shows PTHS's Free Cash Flow at -$6.3 million in Q4 2025, -$15.3 million in Q3 2025, and -$447145.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | -20.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.99 Mn |
| Jun 30, 2026 | -20.99 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Sep 30, 2025 | -15.26 Mn |
| Sep 30, 2025 | -15.26 Mn |
| Jun 30, 2025 | -447,145.00 |
| Jun 30, 2025 | -447,145.00 |
| Mar 31, 2025 | -632,126.00 |
| Mar 31, 2025 | -632,126.00 |
| Dec 31, 2024 | -670,000.00 |
| Dec 31, 2024 | -670,000.00 |
| Sep 30, 2024 | -177,692.00 |
| Sep 30, 2024 | -177,692.00 |
| Jun 30, 2024 | -2.95 Mn |
| Jun 30, 2024 | -2.95 Mn |
| Mar 31, 2024 | -1.99 Mn |
| Mar 31, 2024 | -1.99 Mn |
| Dec 31, 2023 | -356,807.00 |
| Dec 31, 2023 | -356,807.00 |